Home › NDC Lookup › Ingredients › Glipizide › 00591-0460-01
⚪image loading
(from DailyMed)

Glipizide 5 mg Tablet, 100-count — NDC 0591-0460-01 (Billing 00591-0460-01)

by Actavis Pharma, Inc. · 100 TABLET in 1 BOTTLE, PLASTIC

This is a package of 100 tablets of Glipizide 5 mg Tablet from Actavis Pharma, Inc., marketed since Feb 1995 and currently FDA-listed; retail pharmacies pay about $0.0339 per tablet (NADAC).

NDC 00591-0460-01
🏷️ FDA NDC (as labeled) 0591-0460-01 billing pads the labeler segment with a zero
This package
Contains100-count Cost per ea$0.0339 NADAC Per package$3.39 / 100 tablets Pack sizes5 compare ↓
Also priced by: Medicaid pays $0.1290/unit · Part D plans $0.0806/unit — full pricing hub ↓
Product page 00591-0460-10 Also comes in: 500 tablets 0591-0460-05 1000 tablets 0591-0460-10 47500 tablets 0591-0460-00 56952 tablets 0591-0460-77
On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Oct 8, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0591-0460-01 alone.

Record
FDA NDC Directory package listing · Drug for further processing
Code segments
0591 labeler · 0460 product · 01 package
Listing certified through
Dec 31, 2026
Billing quantity
100 EA per package
Barcode (UPC-A, from the NDC)
3 0591046001 3
Medicaid fills, this package
11,480 prescriptions in the last four reported quarters
FDA record last changed
Oct 8, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0591-0460-01
Product NDC 0591-0460
11-digit billing NDC 00591046001
NCPDP billing unit EA — each (per item)
SPL Set ID 08b0d1ae-ce92-4b73-9bdd-61df5d6212ba
DEA schedule Non-controlled
Marketing category DRUG FOR FURTHER PROCESSING
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1995-02-27
Dosage form TABLET
Substance GLIPIZIDE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 27200030000305
GPI class glipiZIDE
GCN Seq No 001777
GCN 10840
HICL code 000803
Ingredient (HICL) Glipizide
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C4
Therapeutic class — intermediate (HIC2) Antihyperglycemics
HIC3 code C4K
Therapeutic class — specific (HIC3) Antihyperglycemic, Insulin-Release Stimulant Type
AHFS code 68:20.20.00
AHFS class Sulfonylureas
FDB label name GLIPIZIDE 5 MG TABLET
FDB brand name Glipizide
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 001777
  • GCN: 10840
  • GPI-14 (Medi-Span): 27200030000305
  • HICL (First Databank): 000803
  • AHFS class code: 68:20.20.00
Why two NDCs? The FDA registers this code as 0591-0460-01 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00591-0460-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name GLIPIZIDE 5 MG TABLET Ingredient Glipizide
📗 Our plain-language guide HelloPharmacist
  • Glipizide helps lower your blood sugar by prompting your pancreas to release more insulin — especially after meals. It's used in type 2 diabetes alongside diet and exercise, not as...
  • What exactly is glipizide supposed to do for my diabetes?
  • The regular tablet works relatively quickly and is usually taken about 30 minutes before a meal. The extended-release tablet (including the brand Glucotrol XL) releases the medicin...
  • What's the difference between the regular tablet and the extended-release tablet?
📖 Read our full Glipizide guide →
1
Nutrient depletion considerations

Glipizide may be associated with lower levels of 1 nutrient — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Glipizide nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.034 $3.39 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.1290 $12.90 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.0806 $8.06 / 100 tablets
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.037 $0.034
▼ Down 8% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00591-0460-01 You're viewing this 100 TABLET in 1 BOTTLE, PLASTIC $0.0339 / ea $3.39 1995-02-27 — Active
00591-0460-05 0591-0460-05 500 TABLET in 1 BOTTLE, PLASTIC $0.0339 / ea $16.94 1995-02-27 — Active
00591-0460-10 0591-0460-10 Main listing 1000 TABLET in 1 BOTTLE, PLASTIC $0.0339 / ea $33.88 1995-02-27 — Active
00591-0460-00 0591-0460-00 47500 TABLET in 1 BAG — — — — Active
00591-0460-77 0591-0460-77 56952 TABLET in 1 CONTAINER — — — — Active

You're viewing the smallest of 5 pack sizes for this product.

This pack has the lowest per-ea cost of the 3 priced pack sizes ($0.0339 NADAC).

This pack accounts for about 11% of this product's recent Medicaid fills; most go to the 1000 tablets pack. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 100-count package — 100 tablet in 1 bottle, plastic.
How does this package differ from NDC 00591-0460-05?
Both are Glipizide 5 mg Tablet — the drug itself is identical. This page's package is the 100-count one, while NDC 00591-0460-05 is the 500 tablets package.
What NDC number is used to bill for this package of Glipizide 5 mg Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Glipizide 5 mgthis 00591-0460-01 Actavis 100 tablets $0.034 — Availability likely —
Glipizide 5 mg 00904-6637-61 Major 100 tablets $0.034 AB Availability likely —
Glipizide 5 mg 50268-0361-15 AvPAK 50 tablets $0.034 AB Availability likely —
Glipizide 5 mg 60505-0141-00 Apotex 100 tablets $0.034 AB Availability likely —
Glipizide 5 mg 60687-0690-01 American 100 tablets $0.034 AB Availability likely —
Glipizide 5 mg 62559-0315-10 ANI 1000 tablets $0.034 AB Availability likely —
Glipizide 5 mg 68645-0574-54 Legacy 30 tablets $0.034 AB Availability likely —
Glipizide 5 mg 69584-0309-10 Oxford 100 tablets $0.034 AB Availability likely —
Glipizide 5 mg 72888-0116-00 Advagen 1000 tablets $0.034 AB Availability likely —
Glipizide 5 mg 00615-8407-05 NCS 15 tablets — AB FDA listed —
Glipizide 5 mg 43353-0207-45 Aphena 45 tablets — AB FDA listed —
Glipizide 5 mg 50090-0502-00 A-S 30 tablets — AB FDA listed —
Glipizide 5 mg 50090-6473-00 A-S 30 tablets — AB FDA listed —
Glipizide 5 mg 50090-6975-00 A-S 90 tablets — AB FDA listed —
Glipizide 5 mg 50090-7755-00 A-S 30 tablets — AB FDA listed —
Glipizide 5 mg 50090-7756-00 A-S 90 tablets — AB FDA listed —
Glipizide 5 mg 50090-7908-00 A-S 90 tablets — AB FDA listed —
Glipizide 5 mg 51407-0620-10 Golden 1000 tablets — AB FDA listed —
Glipizide 5 mg 51655-0180-25 Northwind 60 tablets — AB FDA listed —
Glipizide 5 mg 55154-7987-00 Cardinal 10 tablets — AB FDA listed —
Glipizide 5 mg 55289-0806-93 PD-Rx 180 tablets — AB FDA listed —
Glipizide 5 mg 63629-1398-01 Bryant 100 tablets — AB FDA listed —
Glipizide 5 mg 67046-0236-03 Coupler 30 tablets — AB FDA listed —
Glipizide 5 mg 68071-3548-06 NuCare 60 tablets — AB FDA listed —
Glipizide 5 mg 68071-4085-03 NuCare 30 tablets — AB FDA listed —
Glipizide 5 mg 68071-4223-03 NuCare 30 tablets — AB FDA listed —
Glipizide 5 mg 68071-4857-01 NuCare 100 tablets — AB FDA listed —
Glipizide 5 mg 68071-4939-01 NuCare 100 tablets — AB FDA listed —
Glipizide 5 mg 68788-0141-01 Preferred 100 tablets — AB FDA listed —
Glipizide 5 mg 68788-4020-01 Preferred 100 tablets — AB FDA listed —
Glipizide 5 mg 68788-8512-01 Preferred 100 tablets — AB FDA listed —
Glipizide 5 mg 70518-0552-00 REMEDYREPACK 30 tablets — AB FDA listed —
Glipizide 5 mg 71205-0041-30 Proficient 30 tablets — AB FDA listed —
Glipizide 5 mg 71335-0930-01 Bryant 100 tablets — AB Discontinued —
Glipizide 5 mg 71335-2520-01 Bryant 100 tablets — AB FDA listed —
Glipizide 5 mg 71335-2528-01 Bryant 100 tablets — AB FDA listed —
Glipizide 5 mg 71335-3133-01 Bryant 100 tablets — AB FDA listed —
Glipizide 5 mg 71610-0175-60 Aphena 90 tablets — AB FDA listed —
Glipizide 5 mg 71610-0680-45 Aphena 45 tablets — AB FDA listed —
Glipizide 5 mg 72162-2103-00 Bryant 1000 tablets — AB FDA listed —
Glipizide 5 mg 72789-0130-30 PD-Rx 30 tablets — AB FDA listed —
Glipizide 5 mg 72789-0464-86 PD-Rx 360 tablets — AB FDA listed —
Glipizide 5 mg 82804-0174-30 Proficient 30 tablets — AB FDA listed —
Glipizide 5 mg 82804-0959-00 Proficient 100 tablets — AB FDA listed —
Glipizide 5 mg 66112-0914-01 Piramal 100 tablets — — FDA listed —
Glipizide 5 mg 68788-4178-01 Preferred 100 tablets — AB FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1995
On the market since
Feb 1995
📍
2026
Currently FDA-listed
31 years listed
🔓
·
Generic versions listed
see equivalents
✅Generic appears available

FDA-approved generic versions are listed, and recent pricing/market data suggests they may be available — see Therapeutic equivalents.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Glipizide inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerActavis Pharma, Inc.
Labeler code00591
First marketedFeb 1995
Product typeDrug For Further Processing
Portfolio324 products on file

More NDCs from Actavis Pharma, Inc. labeler code 00591

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full FDA label FDA SPL

The complete FDA label for this product, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
11.5K
Units reimbursed last 4 qtrs
894.2K
Gross reimbursed last 4 qtrs
$115.4K
Avg / prescription
$10.05
Avg / unit
$0.1290
Latest quarter Q1 2026
2.5KRx
Medicaid pays / ea
$0.1290
gross reimbursed
vs
NADAC / ea
$0.0339
acquisition cost
=
Spread
+$0.0951
+281% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
47% FFS 53% MCO
Fee-for-service · 5,385 Rx Managed care · 6,095 Rx
State Medicaid map
Alaska: 2,900 units · 396 per 100k residents AK Maine: 2,490 units · 178 per 100k residents ME Washington: 46,824 units · 599 per 100k residents WA Idaho: 4,785 units · 244 per 100k residents ID Montana: 3,620 units · 320 per 100k residents MT North Dakota: no data reported ND Minnesota: 1,140 units · 19.9 per 100k residents MN Wisconsin: 13,227 units · 224 per 100k residents WI Michigan: 28,575 units · 285 per 100k residents MI New York: 61,957 units · 317 per 100k residents NY Vermont: no data reported VT New Hampshire: 1,608 units · 115 per 100k residents NH Oregon: 36,401 units · 860 per 100k residents OR Nevada: 5,440 units · 170 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 2,979 units · 92.9 per 100k residents IA Illinois: 88,821 units · 708 per 100k residents IL Indiana: 3,242 units · 47.2 per 100k residents IN Ohio: 16,794 units · 143 per 100k residents OH Pennsylvania: 23,143 units · 179 per 100k residents PA New Jersey: 19,905 units · 214 per 100k residents NJ Massachusetts: 6,010 units · 85.8 per 100k residents MA California: 254,821 units · 654 per 100k residents CA Utah: 6,532 units · 191 per 100k residents UT Colorado: 22,982 units · 391 per 100k residents CO Nebraska: 9,372 units · 474 per 100k residents NE Missouri: 16,399 units · 265 per 100k residents MO Kentucky: 11,834 units · 261 per 100k residents KY West Virginia: 8,899 units · 503 per 100k residents WV Virginia: 12,874 units · 148 per 100k residents VA Maryland: 25,851 units · 418 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: 15,205 units · 205 per 100k residents AZ New Mexico: 763 units · 36.1 per 100k residents NM Kansas: no data reported KS Arkansas: 8,952 units · 292 per 100k residents AR Tennessee: 5,288 units · 74.2 per 100k residents TN North Carolina: 10,121 units · 93.4 per 100k residents NC South Carolina: 2,914 units · 54.2 per 100k residents SC Delaware: 885 units · 85.8 per 100k residents DE Oklahoma: 10,364 units · 256 per 100k residents OK Louisiana: 25,880 units · 566 per 100k residents LA Mississippi: 540 units · 18.4 per 100k residents MS Alabama: 6,525 units · 128 per 100k residents AL Georgia: 5,889 units · 53.4 per 100k residents GA D.C.: 7,800 units · 1,149 per 100k residents DC Hawaii: 4,920 units · 343 per 100k residents HI Texas: 15,600 units · 51.1 per 100k residents TX Florida: 9,503 units · 42.0 per 100k residents FL
Units reimbursed · per 100k residents
18.41,149
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 D.C. 1,149 /100k
2 Oregon 860 /100k
3 Illinois 708 /100k
4 California 654 /100k
5 Washington 599 /100k
6 Louisiana 566 /100k
7 West Virginia 503 /100k
8 Nebraska 474 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1000 tablets00591-0460-10 76,258 Rx · $790,479
500 tablets00591-0460-05 15,342 Rx · $163,326
100 tablets this page00591-0460-01 11,480 Rx · $115,358
47500 tablets00591-0460-00 No Medicaid data
56952 tablets00591-0460-77 No Medicaid data
Drug total (last 4 qtrs): 103,080 Rx · 9,668,121 units · $1,069,164 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Glipizide (matched by generic name) — the program that covers self-administered drugs. 8 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Glipizide. CMS lists 4 products for this generic; we show the highest-spend one. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$13.01M
Claims incl. refills
1.1M
Beneficiaries
795.9K
Spend / beneficiary
$16.34
Spend / claim
$12.36
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Listed for further processing / repackaging

What "drug for further processing" means

FDA lists this package under the "drug for further processing" marketing category: Actavis Pharma, Inc. supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Drug For Further Processing". Products approved under an application carry an NDA, ANDA, or BLA number.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Actavis Pharma, Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 4 other package presentations of this same product, including 500 tablets (00591-0460-05), 1000 tablets (00591-0460-10), 47500 tablets (00591-0460-00). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Actavis Pharma, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00591-0453-01 · Actavis 00591-0461-01 · Actavis →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.